

Haematologica  
HAEMATOL/2015/133629  
Version 4

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

Meletios A. Dimopoulos, Matthew C. Cheung, Murielle Roussel, Ting Liu, Barbara Gamberi, Brigitte Kolb, Hans Guenter Derigs, HyeonSeok Eom, Karim Belhadj, Pascal Lenain, Richard Van der Jagt, Sophie Rigaudeau, Mamoun Dib, Rachel Hall, Henry Jardel, Arnaud Jaccard, Axel Tosikyan, Lionel Karlin, William Bensinger, Rik Schots, Nicolas Leupin, Guang Chen, Jennifer Marek, Annette Ervin- Haynes, and Thierry Facon

Disclosures: Disclosures: M.A.D has received honoraria from Celgene, Onyx and Janssen, received research funding from Genesis and Janssen and received travel accommodations/expenses from Celgene, Onyx and Janssen; M.C.C. has received consulting /advisory fees from Gilead; M.R. has received consultancy fees, research funding and lecture fees from Celgene; B.G. has received consulting/advisory fees from Janssen-Cilag, Celgene and Mundipharma; B.K. has received travel accommodations/expenses from Celgene; K.B. has received honoraria from Celgene, Roche and Janssen and travel accommodations/expenses from Celgene and Janssen; R.VdJ. has received honoraria from Celgene, advisory board fees and research funding from Celgene; S.R. has received consulting/advisory fees from Roche and travel accommodations/expenses from Ghugai and Celgene; H.J. has received travel accommodations/expenses from Roche, Celgene, Sandoz and Novartis; A.J. has received honoraria and research funding from Celgene; A.T. has received honoraria from Roche and consulting/advisory fees from Celgene, Janssen and Lunbeck; L.K. is employed by Laboratories Aguettant, has received honoraria from Celgene, Janssen, Amgen, Gilead and Sandoz, travel accommodations/expenses from Celgene and Janssen, and consulting/advisory fees from Celgene, Amgen and Sandoz; W.B. has received honoraria and consulting/advisory fees from Celgene, Bristol Myers and Sandoz, and research funding from Celgene, Bristol Myers, Sandoz, Acetylon, Millennium, Novartis and Pharmacyclics; R.S. has received research funding and travel expenses/accommodations from Celgene; T.F. has received honoraria and consulting/advisory fees from Celgene; N.L., G.C., J.M. and A.E-H are all employed by and have stock/other ownership with Celgene; H.G.D., M.D., H-S.E., T.L., P.L., R. H. all have nothing to disclose.

Contributions: B.K., R.H., N.L., G.C., J.M., A.E-H. and T.F. have made substantial contributions to the concept and design of the manuscript; M.A.D., M.R., P.L., M.C. R.VdJ., A.J., R.S., W.B., N.L., G.C., J.M., A.E-H and T.F. have participated in data analysis and interpretation; T.L., B.G., H.G.D., M.D., H-S.E., K.B., S. R., A. T., L.K., B.K., R.VdJ., H.J., W.B., N.L., G.C., J.M., A.E-H and T.F. have participated in collection and assembly of the data; M.A.D., M.R., P.L., M.C., T.L., B.G., H.G.D., M.D., H-S.E., K.B., S. R., A. T., L.K., B.K.,R.VdJ., R.H., H.J., A.J., R.S., N.L., G.C., J.M., A.E-H. and T.F. have drafted the article or revised it critically for important intellectual content; M.A.D., M.C., M.R., T.L., B.G., B.K., H.G.D., H-S.E., K.B., P.L., R.VdJ., S.R., M.D., R.H., H.J., A.J., A.T., L.K., W.B., R.S., N.L., G.C., J.M. and A.E-H and T.F. have given final approval of the version of the manuscript for submission.